Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGD013 +/- Brivanib in Advanced Liver Cancer
NCT04212221Phase 2Terminated
- Sponsor
- Zai Lab
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tebotelimab in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), sponsored by Zai Lab. Started Apr 2020; status: terminated.
02
Drugs
tebotelimab
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04212221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212221.